Going past the data for temozolomide.

J Lee Villano, Nathalie Letarte, Linda R Bressler

Department of Medicine, Section of Hematology/Oncology, University of Illinois at Chicago, 840 S Wood St Rm 839, M/C 713, Chicago, IL 60612, USA. jvillano@uic.edu

Cancer chemotherapy and pharmacology 2012 Apr

filter terms:

The benefit of six cycles of adjuvant temozolomide was documented in a randomized phase III (EORTC-NCIC CE.3) trial, and this therapy, following combined temozolomide and radiation, is the standard of care for patients with newly diagnosed glioblastoma. We comment on the differences in the length of adjuvant therapy in both clinical practice and national studies (e.g. RTOG 0825), usually doubling the length in the EORTC/NCIC study, and relate to historic adjuvant trials for solid tumors.

Citation

J Lee Villano, Nathalie Letarte, Linda R Bressler. Going past the data for temozolomide. Cancer chemotherapy and pharmacology. 2012 Apr;69(4):1113-5